Towe Eric C, Bos J Martijn, Ommen Steve R, Gersh Bernard J, Ackerman Michael J
Department of Pediatrics, Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minn, USA.
Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minn, USA.
Congenit Heart Dis. 2015 May-Jun;10(3):E139-45. doi: 10.1111/chd.12242. Epub 2014 Dec 14.
Hypertrophic cardiomyopathy is underscored by profound phenotypic and genotypic heterogeneity. Echocardiographically, hypertrophic cardiomyopathy can be categorized into four morphological subtypes: reverse curve, sigmoidal, neutral contour, and apical variant. Previous studies indicate that reverse curve hypertrophic cardiomyopathy is the strongest predictor of a positive genetic test. Little is known about the spectrum and prevalence of mutations and genotype-phenotype correlations in apical hypertrophic cardiomyopathy.
Between 1999 and 2007, 1053 patients with the diagnosis of hypertrophic cardiomyopathy (60% male, age at diagnosis 44.4 ± 19 years) underwent sarcomeric genetic testing. Blinded to the genetic test results, each echocardiogram was scored for septal morphology and phenotyping was performed using the patient's medical record. Subset analysis was performed to elucidate the genotype, phenotype, and outcome of apical hypertrophic cardiomyopathy.
Overall, 71 patients (7%) had apical hypertrophic cardiomyopathy on echocardiography (63% male, mean age 47.8 ± 15 years, mean left ventricular wall thickness 19.8 ± 6 mm). Left ventricular outflow tract obstruction was uncommon (seven patients; 10%). Eighteen patients (25%) had a positive genetic test, with the majority of mutations found in MYBPC3 (six; 35%) and MYH7 (six; 35%). Follow-up was available on 68 patients (96%) with a median age of 57.3 years (range 19.3-82 years). Mean follow-up was 5.5 years (range 0.1-18.2 years). There was no statistical difference between the occurrence rates of adverse events between genotype-positive and genotype-negative groups.
In this largest cohort of patients with genetic testing for hypertrophic cardiomyopathy, <10% exhibited apical disease. This least common subtype was associated with a negative genetic test result 75% of the time. In contrast to prior publications suggesting a predilection for ACTC1/TPM1 mutations in patients with apical hypertrophic cardiomyopathy, the two most common genotypes (MYBPC3-HCM and MYH7-HCM) remained most common among patients who had a positive genetic test.
肥厚型心肌病具有显著的表型和基因型异质性。在超声心动图检查中,肥厚型心肌病可分为四种形态学亚型:反曲线型、S形、中性轮廓型和心尖变异型。先前的研究表明,反曲线型肥厚型心肌病是基因检测呈阳性的最强预测指标。关于心尖肥厚型心肌病的突变谱、患病率以及基因型与表型的相关性,目前所知甚少。
1999年至2007年间,1053例诊断为肥厚型心肌病的患者(60%为男性,诊断时年龄44.4±19岁)接受了肌节基因检测。在不知基因检测结果的情况下,对每一份超声心动图的室间隔形态进行评分,并根据患者病历进行表型分析。进行亚组分析以阐明心尖肥厚型心肌病的基因型、表型和预后情况。
总体而言,71例患者(7%)超声心动图显示为心尖肥厚型心肌病(63%为男性;平均年龄47.8±15岁;平均左心室壁厚度19.8±6mm)。左心室流出道梗阻并不常见(7例患者;10%)。18例患者(25%)基因检测呈阳性,大多数突变见于MYBPC3(6例;35%)和MYH7(6例;35%)。68例患者(96%)有随访资料,中位年龄57.3岁(范围19.3 - 82岁)。平均随访时间为5.5年(范围0.1 - 18.2年)。基因型阳性组和基因型阴性组不良事件发生率无统计学差异。
在这个接受肥厚型心肌病基因检测的最大患者队列中,<10%表现为心尖部病变。这种最不常见的亚型在75%的情况下基因检测结果为阴性。与先前发表的提示心尖肥厚型心肌病患者倾向于发生ACTC1/TPM1突变的文献相反,在基因检测呈阳性的患者中,两种最常见的基因型(MYBPC3 - HCM和MYH7 - HCM)仍然最为常见。